The FDA just removed black-box warnings about breast cancer, cardiovascular disease and dementia from three more estrogen patches. When journalists asked to see the evidence behind the decision, officials said it could be provided later. Later is a bold timeline for a drug safety label that is already off the patch.
Evidence Available Upon Request, Eventually
On Friday, officials at the US Food and Drug Administration announced that three more menopause patches will no longer carry black-box warnings about cardiovascular disease, breast cancer and dementia, according to The Guardian. The agency did not convene an advisory committee. It offered few details on the scientific basis for the call during the press briefing.
So reporters did the obvious thing and asked for the evidence. The answer was that it could be provided later.
This is the black box. The strongest warning the agency can put on a drug label. You would think the paperwork for taking one off might be sitting on the table when you announce it. Apparently you would be wrong.
Round Two of Skipping the Homework
This is not the first time. In February, the agency removed black-box warnings from six menopause treatments. Friday's announcement adds three more patches to the pile, and officials said they are working to change the labels on the remaining hormone therapy products too.
The pattern is the point. The FDA bypassed its advisory committees last November when it announced it would strip these warnings. A spokesperson explained at the time that the committees are "bureaucratic, long, often conflicted, and very expensive."
Conflicted. Hold that word, because we are about to need it.
The Panel Was Hand-Picked and the Mic Was Off
Instead of its advisory committees, the FDA convened a panel in July 2025 featuring doctors and influencers. According to Reshma Ramachandran, an assistant professor and health services researcher at Yale School of Medicine, all of them were vocal proponents of menopause hormone therapy. Several had conflicts of interest with practices that market and sell hormone therapy.
So the agency dodged its standing committees for being conflicted and replaced them with a panel of people who sell the stuff. That is not a fix. That is a rebrand.
It gets worse. Ramachandran said the meeting did not allow public testimony, including from the lead investigator of the Women's Health Initiative, the research that formed the recommendations for hormone therapy in the first place. That person was in the audience. They were in the room, and they were not allowed to speak. Only after audience members voiced concern did the FDA open a docket for public comment.
Nobody Is Saying Patches Are Poison
Let's be fair here, because the facts deserve it. Estradiol patches are usually considered lower risk than synthetic oral medications because they pass into the bloodstream without first going through the liver. FDA official Sarah Ibrahim argued the old warnings painted a broad and, in some cases, overstated picture of risk. She said updated evidence shows that for many healthy women under 60 and within 10 years of menopause onset, the risk-benefit profile looks meaningfully different.
That may well be true for a lot of patients. Menopause experts agree there are real benefits for some women.
But the research also shows the risks of patches rise at high doses. And Ramachandran warned that certain groups, such as women with histories of hormone-sensitive cancers, face particular risks. A blanket removal of the warnings without clear justification, she said, can be misleading for patients and underplays real potential harms. A targeted, evidence-backed label update is one thing. This is a sledgehammer swung in a press briefing.
Data-Free Claims and Empty Pharmacy Shelves
Menopause experts say officials in the Trump administration have made sweeping and data-free claims about the benefits of hormone therapy, including improvements in longevity that research does not support. Pair that with a decision made without advisers or published evidence and you get the precedent experts are worried about.
Meanwhile, the practical results are landing on patients. Since the February label change, demand for estradiol patches has surged, and people across the country are struggling with shortages. Ibrahim acknowledged it on Friday: patients in many areas found it hard to get their usual patches at their usual pharmacy. "I want you to know that we hear you," she said. Dorothy Fink, deputy director of the National Institute of Child Health and Human Development, said manufacturing of estrogen patches has doubled over the past year. Patients still report stock-outs.
So the agency boosted demand with a label change, the supply could not keep up, and now the response to empty shelves is to remove warnings from three more patches. The FDA is also exploring offering vaginal estrogen products over the counter. Everyone loves a sequel.
The Dingo Take
The FDA announced a major drug safety change, was asked for the science, and said it would get back to us. That is the whole story. Everything else is detail, and the details are not flattering.
Here is what it adds up to. An agency decided its own advisory committees were too conflicted, then consulted a panel stocked with proponents who have commercial ties to hormone therapy, then refused to let the lead investigator of the foundational research speak, then dropped the warnings and left the evidence for later. At every step, the process was designed to avoid the one thing a process is supposed to do, which is test the conclusion before announcing it.
Maybe the science holds up. Maybe many healthy women under 60 really were scared away from something that would help them. Fine. Then show the work. If the case is strong, a public committee and published data would only make it stronger. The refusal to do that tells you more than any press briefing could. When an agency is this allergic to scrutiny, the problem is not the paperwork. The problem is what the paperwork might say.
Comments